Search All Tech Briefings

Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available. Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 26 Results

Clear All Filters

Title	Intervention	Indication	Therapeutic Area	Year	Actions
Amivantamab with chemotherapy for previously untreated advanced EGFR exon 20 insertion mutations positive non-small cell lung cancer	Amivantamab (JNJ-6372; JNJ-61186372) , Chemotherapy	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2022	View \| Download
Atezolizumab with chemotherapy for treating recurrent triple-negative breast cancer	Atezolizumab (Tecentriq; MPDL3280A) , Chemotherapy	Breast cancer	Breast Cancer	2022	View \| Download
Atezolizumab with platinum-based chemotherapy and bevacizumab for epithelial ovarian cancer or fallopian tube cancer or primary peritoneal cancer	Atezolizumab (Tecentriq; MPDL3280A) , Bevacizumab (Avastin; R 435; RG 405; RG 435) , Chemotherapy	Epithelial ovarian cancer , Fallopian tube cancer , primary peritoneal cancer	Female Reproductive Cancer	2022	View \| Download
Blinatumomab with chemotherapy for frontline consolidation treatment of Philadelphia chromosome negative, measurable residual disease negative, B-lineage acute lymphoblastic leukaemia	Blinatumomab (Blincyto) , Chemotherapy	Acute lymphoblastic leukaemia (ALL)	Haematological Cancer and Lymphomas	2024	View \| Download
Brentuximab vedotin with chemotherapy (BrECADD) for previously untreated advanced classical Hodgkin lymphoma	Brentuximab vedotin (Adcetris; SGN-35) , Chemotherapy	Hodgkin lymphoma	Haematological Cancer and Lymphomas	2024	View \| Download
Dostarlimab with chemotherapy and niraparib for treating advanced epithelial ovarian cancers – first line	Chemotherapy , Dostarlimab (TSR-042; Jemperli) , Niraparib (Zejula; MK 4827; JNJ 64091742; GSK 3985771; niraparib tosylate monohydrate)	Epithelial ovarian cancers	Female Reproductive Cancer	2023	View \| Download
Durvalumab in addition to chemotherapy for metastatic non-small-cell lung cancer - first line	Chemotherapy , Durvalumab (Imfinzi; MEDI4736; MEDI-4736; MEDI 4736)	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2019	View \| Download
Durvalumab with bevacizumab and chemotherapy for treating advanced ovarian cancers	Bevacizumab (Avastin; R 435; RG 405; RG 435) , Chemotherapy , Durvalumab (Imfinzi; MEDI4736; MEDI-4736; MEDI 4736)	Ovarian cancer	Female Reproductive Cancer	2023	View \| Download
Durvalumab with platinum-based chemotherapy for the neoadjuvant/adjuvant treatment of resectable non-small-cell lung cancer	Chemotherapy , Durvalumab (Imfinzi; MEDI4736; MEDI-4736; MEDI 4736)	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2022	View \| Download
Neoadjuvant atezolizumab with chemotherapy followed by adjuvant atezolizumab for treating triple-negative breast cancer	Atezolizumab (Tecentriq; MPDL3280A) , Chemotherapy	Breast cancer	Breast Cancer	2022	View \| Download